Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Allantoic Split Inactivated Seasonal Influenza Vaccine in Healthy Adults
NCT03572491Phase 3Completed
- Sponsor
- Research Institute for Biological Safety Problems
- Start
- Sep 2017
- Primary completion
- May 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of ARCT-2138 in influenza (2 arms), sponsored by Research Institute for Biological Safety Problems. Primary endpoint: Preventive efficacy - Incidence of influenza among vaccinated and unvaccinated volunteers at 180 days. Started Sep 2017; status: completed.
02
Drugs
ARCT-2138
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03572491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03572491.